Wed, 4 Nov
Anthem Biosciences
Anthem delivered robust Q2 results driven by CRDMO business and sharp margin expansion. Management highlighted strong operating leverage and cost discipline while scaling capacity.
Summary ready
Earnings calls
Anthem Biosciences concalls
Every Anthem Biosciences earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Anthem delivered robust Q2 results driven by CRDMO business and sharp margin expansion. Management highlighted strong operating leverage and cost discipline while scaling capacity.
Outlook
Ongoing ₹1,200 Cr Capex for Unit 4 to double current capacity by FY28.
Earlier call summaries
All →
18:07 IST
BSE
Earnings Call
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
15:44 IST
BSE
Earnings Call
Anthem Biosciences Earnings Call: Key Takeaways
Anthem Biosciences delivered record Q4 performance with FY26 revenue of ₹2,280cr and 43.4% EBITDA margins, driven by CRDMO strength.
18:10 IST
BSE
Earnings Call
Anthem Biosciences Earnings Call: Key Takeaways
Anthem delivered robust FY26 growth, overcoming destocking challenges in their core CRDMO segment.
19:35 IST
BSE
Earnings Call
Anthem Biosciences Earnings Call: Key Takeaways
Anthem Biosciences achieved record Q4FY26 revenue of ₹6,109 Mn. The company delivered 15.2% FY26 revenue growth with strong EBITDA margins of 43.4% driven by its CRDMO segment.
19:29 IST
NSE
Earnings Call
Anthem Biosciences Earnings Call: Key Takeaways
Anthem Biosciences delivered a high-growth Q1 FY26, leveraging its commercialized molecule portfolio and strong cash position. Management is balancing aggressive capacity expansion with optimistic 20% long-term growth aspirations despite near-term lumpiness.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹888.30
- Market cap
- ₹50,029 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 81.5×Sector 41.3×
- Promoter holding
- 71.40%-0.02% QoQ
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.